French start-up CliniGenetics SA has devised an integrated pharmacogenomics and bioinformatics technology platform to identify gene and protein targets associated with vascular diseases. The company hopes to use those targets to devise novel therapies and diagnostics.
You may also be interested in...
The history of the IIb/IIIa inhibitor Integrilin touches on many of the challenges of cardiology marketing, including how to move a member of a new class of drugs into a complex, rapidly evolving treatment pattern. Having established Integrilin as the most-used drug in its class, its marketer must now deal with the impact on IIb/IIIa use of Angiomax, a potential replacement for heparin. Imagine the scene five years from now: A combination of Angiomax and low-molecular-weight heparin has replaced unfractionated heparin, and the addition of statins and possibly vascular protectants has turned the current triple therapy regimens of anti-coagulants, anti-thrombins, and anti-platelet drugs into a quartet. Physicians attending scientific meetings may well still be puzzling over the proper role of IIb/IIIa inhibitors, and asking themselves the extent to which long-term results from trials initiated early in the 21st century have meaning.
By marrying gene therapy with medical device technology, Sweden's Xenerate AB believes it can make implantable vascular devices--artificial grafts and stents--capable of endothelialization, thus improving their biocompatibility and reducing the incidence of intimal hyperplasia, restenosis and other adverse effects.
Arexis is using specially designed animal models to unravel the genetics of metabolic disease.